What Is COPD?
Chronic obstructive pulmonary disease (COPD) is a preventable and treatable chronic respiratory disease, characterized by persistent airflow obstruction that is generally progressive and associated with a chronic inflammatory response of the airways and pulmonary parenchyma to noxious particles or gases.
COPD is the third leading cause of death worldwide, responsible for more than 3 million deaths annually. It is one of the leading causes of hospitalization globally. Smoking is the dominant risk factor, causing 80-90% of cases.
COPD encompasses two pathologic processes that often coexist: chronic obstructive bronchitis (inflammation and narrowing of the airways with mucus hypersecretion) and pulmonary emphysema (destruction of alveolar septa with loss of gas exchange area and hyperinflation). The relative contribution of each component varies among patients.
Irreversible Obstruction
Unlike asthma, airflow obstruction in COPD is persistent and minimally reversible with a bronchodilator. It is demonstrated by post-bronchodilator FEV1/FVC < 0.7 on spirometry.
Systemic Disease
COPD affects more than the lungs. It causes systemic inflammation, muscle mass loss, osteoporosis, depression, and increased cardiovascular risk.
Underdiagnosed
Up to 70% of COPD patients do not know they have the disease. Early diagnosis by spirometry and smoking cessation can drastically alter the natural history.
Pathophysiology
Chronic inhalation of cigarette smoke provokes an amplified inflammatory response in the airways and pulmonary parenchyma. Alveolar macrophages, neutrophils, and cytotoxic CD8+ T lymphocytes are recruited and release proteases (neutrophil elastase, MMP-9, MMP-12) that destroy elastin and collagen of the lung tissue.
The protease-antiprotease imbalance is central to the pathogenesis of emphysema. Alpha-1-antitrypsin, the main inhibitor of neutrophil elastase, is inactivated by oxidants from cigarette smoke. In 1-3% of cases, genetic alpha-1-antitrypsin deficiency (PiZZ phenotype) causes early emphysema, especially panlobular and at the lung bases.
Emphysema and Air Trapping
Destruction of the alveolar septa in emphysema reduces the surface area for gas exchange (from 70 m² to less than 40 m² in severe cases) and eliminates the elastic fibers that maintain radial traction on the small airways. Without this traction, the airways collapse during expiration, causing air trapping (hyperinflation).
Dynamic hyperinflation — worsening of air trapping during exercise — is the main mechanism of exertional dyspnea in COPD. The lowered, flattened diaphragm operates at a mechanical disadvantage, increasing the work of breathing and the sensation of breathlessness.
Symptoms
The symptoms of COPD are insidious and progressive. Chronic dyspnea is the most disabling symptom, while cough with sputum production may precede obstruction by years. The patient frequently limits activities unconsciously to avoid dyspnea, delaying diagnosis.
Symptoms of COPD
- 01
Progressive chronic dyspnea
Initially only with great exertion; progresses to limit basic activities such as dressing or bathing. Assessed by the mMRC scale (0-4).
- 02
Chronic cough with sputum production
Productive morning cough, often the first symptom. Sputum is mucoid during stable periods and purulent during exacerbations.
- 03
Wheezing and chest tightness
Expiratory wheezing from airway narrowing. May vary day to day and worsen with exercise or infections.
- 04
Acute exacerbations
Sustained worsening of symptoms beyond daily variation, requiring a treatment change. Often precipitated by viral or bacterial infections.
- 05
Weight loss and sarcopenia
Progressive muscle mass loss in advanced COPD — respiratory energy expenditure can rise 10-fold above normal.
- 06
Anxiety and depression
Depression prevalence of 25-40% and anxiety prevalence of 20-35% in COPD. Often underdiagnosed and undertreated.
Diagnosis
Diagnosis of COPD requires post-bronchodilator spirometry demonstrating FEV1/FVC less than 0.7. Severity is classified by post-bronchodilator FEV1: GOLD 1 (mild, FEV1 ≥ 80%), GOLD 2 (moderate, 50-79%), GOLD 3 (severe, 30-49%), and GOLD 4 (very severe, below 30%).
The GOLD ABE classification (2024) integrates spirometry, symptoms (mMRC scale or CAT), and exacerbation history to guide treatment. Complementary tests include chest radiograph, arterial blood gas, serum alpha-1-antitrypsin, and complete blood count (compensatory polycythemia).
🏥Diagnostic Confirmation of COPD
- 1.Post-bronchodilator spirometry with FEV1/FVC < 0.7 (mandatory criterion)
- 2.History of exposure to risk factors (smoking, biomass, occupational)
- 3.Compatible symptoms (dyspnea, chronic cough, sputum production)
- 4.Severity classification: GOLD 1-4 by post-bronchodilator FEV1
- 5.Combined GOLD ABE classification integrating symptoms and exacerbations
DIAGNÓSTICO DIFERENCIAL
Differential Diagnosis
Bronchial Asthma
Younger onset, post-bronchodilator reversible obstruction, eosinophilia, atopy, no history of heavy smoking
Bronchiectasis
Abundant chronic purulent sputum, recurrent infections, CT with bronchial dilation and thickening
Heart Failure
Orthopnea, paroxysmal nocturnal dyspnea, bilateral edema, basal crackles, elevated BNP, cardiomegaly
Bronchial Carcinoma
Change in cough pattern, hemoptysis, weight loss, hilar or mediastinal adenopathy; systematic CT in smokers
Bronchiolitis Obliterans
History of lung or marrow transplant, exposure to toxic gases; CT shows mosaic pattern with air trapping
Asthma-COPD Overlap (ACO)
Asthma-COPD overlap (ACO) occurs when a patient shows features of both diseases. It is more common in elderly people (over 50-60 years) with a history of smoking and asthma, or in adults with COPD who show a significant reversible component. These patients have worse prognosis than asthma or COPD alone: more exacerbations, greater lung function decline, and elevated mortality.
ACO treatment combines the pillars of both diseases: inhaled corticosteroid (essential for the asthma component) plus long-acting bronchodilators (LAMA and LABA, essential for COPD). Never use LABA without ICS in ACO — it increases mortality risk. The pulmonologist is the ideal specialist for managing this complex condition.
Heart Failure in COPD
Heart failure is an extremely common comorbidity in COPD — up to 30% of COPD patients have concomitant CHF. It can both mimic COPD exacerbations and precipitate them. The distinction is clinically challenging, since both cause progressive dyspnea, exercise intolerance, and nocturnal worsening.
Serum BNP or NT-proBNP are essential for the distinction: very elevated values favor decompensated CHF. Echocardiography is essential. In exacerbations refractory to bronchodilator treatment, always consider CHF as a cause or aggravating factor. Diuretic plus ACE inhibitor/ARB can be dramatically effective when CHF is the predominant component.
Alpha-1-Antitrypsin Deficiency
Alpha-1-antitrypsin deficiency (AATD) is the most common form of genetic lung disease in adults and causes early COPD/emphysema in non-smokers or light smokers. Investigate it in: emphysema with onset before age 45, emphysema predominantly in lung bases (versus apices in smoking-related COPD), COPD in a non-smoker without clear occupational exposure, or family history of early emphysema.
Diagnosis is confirmed by serum alpha-1-antitrypsin measurement (below 57 mg/dL suggests significant deficiency) and by genotyping. The PiZZ phenotype is the most severe and may receive replacement therapy with intravenous alpha-1-antitrypsin in selected cases. Smoking cessation is absolutely imperative in these patients.
Treatment
Smoking cessation is the only measure with demonstrated effect in reducing the rate of FEV1 decline and improving survival. Pharmacologic treatment aims to relieve symptoms, improve exercise tolerance, and reduce exacerbations.
Group A: Few Symptoms, Few Exacerbations
Short- or long-acting bronchodilator as needed. LAMA (tiotropium) or LABA (salmeterol, formoterol) preferred for regular use. Smoking cessation and vaccination.
Group B: More Symptoms, Few Exacerbations
Combined LAMA + LABA. Dual bronchodilator therapy (LAMA/LABA) outperforms monotherapy for symptoms and lung function. Pulmonary rehabilitation is mandatory.
Group E: Frequent Exacerbations
LAMA/LABA as first choice. If blood eosinophils ≥ 300/mcL, consider triple therapy (LAMA/LABA/ICS). Roflumilast and azithromycin for exacerbator phenotypes. Biologics under study.
Non-Pharmacologic Measures
Pulmonary rehabilitation (reduces dyspnea and exacerbations), long-term home oxygen therapy (when PaO2 ≤ 55 mmHg), home noninvasive ventilation, lung volume reduction surgery, or transplant in selected cases.
Acupuncture as Treatment
Acupuncture in COPD has been investigated as an adjuvant, with proposed targets of reduction of dyspnea, improvement of exercise tolerance, and quality of life. Proposed mechanisms — still hypothetical — include possible modulation of central respiratory pathways, relaxation of accessory musculature, and neuromodulatory effect.
Some meta-analyses suggest that acupuncture, as a complement to standard treatment, may be associated with improved Borg scale scores and 6-minute walk test distance, with modest magnitudes and heterogeneous evidence quality. It does not change FEV1 in a clinically relevant way and does not alter the disease's natural history.
Acupuncture does not replace bronchodilators, pulmonary rehabilitation, or oxygen therapy. It is a complementary therapy that may help especially with refractory dyspnea and disease-associated anxiety. Regular sessions, integrated into a pulmonary rehabilitation program, seem to offer the best results.
Prognosis
COPD is a progressive disease. FEV1 decline in active smokers is 40-60 mL/year, versus 25-30 mL/year in non-smokers. Smoking cessation returns the decline rate to normal but does not recover function already lost.
The BODE index (Body mass index, Obstruction, Dyspnea, Exercise capacity) is the best mortality predictor. Patients with BODE 7-10 have a median survival of 3 years. Long-term home oxygen therapy is the only intervention beyond smoking cessation with a demonstrated survival benefit in hypoxemic COPD.
Pulmonary rehabilitation does not directly change survival but dramatically improves quality of life and exercise capacity and reduces hospitalizations. Lung transplant is an option for young patients with very severe COPD who continue to deteriorate despite optimized treatment.
Myths and Facts
Myth vs. Fact
COPD is just emphysema in old smokers
COPD can affect non-smokers (biomass, pollution, or occupational exposure) and may appear before age 50, especially in alpha-1-antitrypsin deficiency.
It is no use stopping smoking once you have COPD
Smoking cessation at any stage of COPD slows lung function loss, decreases exacerbations, and significantly improves survival.
Shortness of breath is a normal consequence of aging
Progressive dyspnea is not normal at any age. It may be the first sign of COPD and should be investigated with spirometry in smokers or ex-smokers.
COPD has no treatment — it only worsens with time
Effective treatments relieve symptoms, improve quality of life, and reduce exacerbations. Pulmonary rehabilitation has a transformative impact on function.
Oxygen causes dependence and should be avoided
Home oxygen therapy for hypoxemic COPD is the only treatment with a demonstrated life expectancy benefit. It does not cause dependence — it corrects a physiologic deficiency.
When to Seek Help
Severe COPD exacerbations are potentially fatal and require immediate care.
Frequently Asked Questions
Yes — COPD has effective treatment, though no cure. Long-acting bronchodilators (LAMA, LABA), pulmonary rehabilitation, and smoking cessation can significantly relieve symptoms, reduce exacerbations, and improve quality of life. Smoking cessation is the only measure that alters the disease's natural history.
Yes, as complementary therapy. Medical acupuncture may reduce dyspnea (measured by the Borg scale) and improve exercise tolerance and quality of life. Integrated into a pulmonary rehabilitation program, it amplifies the gains from physical exercise. It never replaces bronchodilators or oxygen therapy.
Asthma has reversible obstruction, eosinophilic inflammation, and often begins in childhood. COPD has progressive irreversible obstruction, neutrophilic inflammation, and occurs predominantly in smokers over age 40. The two can coexist (ACO), especially in elderly smokers with asthma.
Dramatically so. Smoking cessation is the most important intervention at any stage of COPD. It slows FEV1 decline to non-smoker levels, decreases exacerbations, improves survival, and eases symptoms. It is never too late to quit — even in severe COPD, the benefits are significant.
Exacerbations are episodes of acute symptom worsening (cough, sputum production, dyspnea) beyond daily variation, requiring a treatment change. Usually precipitated by viral or bacterial infections. Each exacerbation accelerates lung function loss and worsens prognosis. Preventing exacerbations is a central therapeutic goal.
No. Oxygen corrects a physiologic deficiency — low blood oxygenation (hypoxemia). Long-term home oxygen therapy (more than 15 hours per day) in hypoxemic COPD is the only intervention beyond smoking cessation with a demonstrated life expectancy benefit. It does not cause dependence — it is an essential treatment.
A multidisciplinary program that combines aerobic exercise (bicycle, treadmill), respiratory muscle training, disease education, and psychosocial support. It reduces dyspnea, improves exercise tolerance and quality of life, and decreases hospitalizations. Recommended for all patients with moderate to severe COPD.
Yes. Biomass exposure (wood stoves, charcoal in closed environments), air pollution, occupational dust and gas exposure, and genetic alpha-1-antitrypsin deficiency can all cause COPD in non-smokers. In Brazil, biomass exposure is an important cause, especially in women from rural areas.
The BODE index integrates four variables: B (BMI — Body mass index), O (obstruction by FEV1), D (dyspnea by the mMRC scale), and E (exercise — distance on the 6-minute walk test). It is the best mortality predictor in COPD. A score of 7-10 indicates a very poor prognosis with median survival of 3 years.
Lung transplant is considered in young patients (generally under age 65) with very severe COPD (GOLD 4) refractory to optimized treatment, with severely impaired quality of life and no contraindications to the procedure. Specialized transplant centers handle the evaluation. Smoking cessation for at least 6 months is mandatory.
Related Reading
Deepen your knowledge with related articles